THC vs. THC-COOH — What Drug Tests Actually Measure

Standard cannabis urine drug tests do not detect THC. They detect THC-COOH (11-nor-9-carboxy-THC), an inactive metabolite produced by the liver as it breaks THC down. Understanding this distinction is the single most important scientific fact about cannabis drug testing.

The Distinction in One Sentence

THC makes you high; THC-COOH is the molecule your liver creates when your body is done with THC — it produces zero psychoactive effects, but it is exactly what labs measure in urine drug tests.

The Metabolic Pathway

When cannabis enters the bloodstream, the liver immediately begins processing it through a series of enzyme reactions. The simplified pathway looks like this:

Δ9-THC (the psychoactive compound) — this is what makes you feel high
Hepatic oxidation via CYP450 enzymes produces 11-hydroxy-THC (11-OH-THC) — also psychoactive, approximately equipotent to THC
Further oxidation produces THC-COOH (11-nor-9-carboxy-THC) — pharmacologically inactive, no psychoactive effects
Glucuronide conjugation in the liver produces THC-COOH-glucuronide, the water-soluble form
This is excreted in urine (~20%) and feces (~65%) over days to weeks

Standard immunoassay urine tests measure total THC-COOH (both free and glucuronide-conjugated forms, after an enzymatic hydrolysis step). Confirmation testing by GC-MS or LC-MS/MS typically targets free THC-COOH at specific retention times and mass spectral fragments.

Why THC-COOH, Not THC?

There is a practical reason labs measure the metabolite rather than the parent drug: THC itself is very short-lived in urine. The parent drug has a short plasma half-life and is not efficiently excreted in urine because it is highly lipophilic. By the time a urine sample is collected and tested, there is essentially no parent THC to detect — but THC-COOH accumulates and remains detectable for much longer. Measuring the metabolite gives labs a longer and more practical detection window.

The tradeoff is that you lose any connection to current impairment. THC's psychoactive effects typically last 2–6 hours after inhalation and can last 6–12 hours after ingestion. THC-COOH, by contrast, remains detectable for days to weeks. A person who smoked a joint last Friday night is entirely sober on Monday morning, but their urine will still contain THC-COOH.

Blood and saliva tests are different. They can detect parent THC, which gives them a shorter detection window but a closer (though still imperfect) relationship to recent use. Urine testing dominates workplace and probation testing because of its logistical advantages, not because it is the most impairment-relevant test.

The "Inactive" Part Matters

THC-COOH has been extensively studied pharmacologically. It does not bind meaningfully to the CB1 or CB2 cannabinoid receptors. It produces no psychoactive effects in humans, and its only known biological activities are as a marker of prior cannabis exposure. This is not a marginal scientific claim — it is a settled finding from decades of pharmacology research.

11-OH-THC, the intermediate metabolite, is a different story. It is psychoactive, and in fact plays a significant role in the subjective effects of edible cannabis (because the first-pass hepatic metabolism after oral ingestion produces proportionally more 11-OH-THC than inhaled cannabis does). But 11-OH-THC is itself short-lived and is not the primary target of urine drug tests.

Huestis MA, Henningfield JE, Cone EJ. "Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana." Journal of Analytical Toxicology 1992;16(5):276-282.. PMID: 1338215

The Implications

A positive test proves past exposure, not current impairment. This is a scientific fact, not an opinion.
Metabolite-based testing is well-suited to asking "did you use cannabis recently?" — not "are you currently impaired?"
Employers and courts often treat the two questions as interchangeable. The science does not support that.
Some state laws now specifically address this gap. California's AB 2188 (effective 2024) prohibits employers from acting on tests that detect only nonpsychoactive metabolites — explicitly recognizing that THC-COOH does not prove impairment. See California's page for details.